Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 229

Results For "SEC"

2687 News Found

VivaLyf Innovations to launch EzLyf, India's first non-invasive glucometer
Startup | December 30, 2021

VivaLyf Innovations to launch EzLyf, India's first non-invasive glucometer

The glucometer connects to one’s smartphone and provides actionable diagnostic information


Siemens Healthineers receive EUA for Covid-19 antigen self-test
Medical Device | December 30, 2021

Siemens Healthineers receive EUA for Covid-19 antigen self-test

Rapid antigen testing provides results in just 15 minutes and the information can help reduce the risk of Covid-19 exposure


G42 Healthcare, Abu Dhabi and AstraZeneca to collaborate on clinical research
Biotech | December 29, 2021

G42 Healthcare, Abu Dhabi and AstraZeneca to collaborate on clinical research

G42 Healthcare and AstraZeneca will work closely together to explore real-world evidence and conduct clinical trials through IROS – the first-of-its-kind Contract Research Organization (CRO) in the UAE


Expectations and predictions for 2022
Opinion | December 28, 2021

Expectations and predictions for 2022

In India, healthcare has become one of the fastest-growing economic sectors which comprise hospitals, pharma companies, medical equipment and devices, medical tourism, health insurance, clinical trials etc


Cipla receives EUA for Cipmolnu
Drug Approval | December 28, 2021

Cipla receives EUA for Cipmolnu

The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use


CDSCO expert committee recommends Emergency Use Authorisation to Covovax and Corbevax
News | December 28, 2021

CDSCO expert committee recommends Emergency Use Authorisation to Covovax and Corbevax

All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.


Trastuzumab deruxtecan type II variation application validated by EMA
Biotech | December 28, 2021

Trastuzumab deruxtecan type II variation application validated by EMA

Application based on DESTINY-Breast03 results showing Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan reduced risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1)


Covaxin receives approval for Emergency Use in Children 12-18 years
Drug Approval | December 27, 2021

Covaxin receives approval for Emergency Use in Children 12-18 years

Covaxin is formulated uniquely such that the same dosage can be administered to adults and children


Novavax and SK bioscience expand manufacturing agreement
Biotech | December 24, 2021

Novavax and SK bioscience expand manufacturing agreement

SK bioscience secures long-term license to supply the Novavax vaccine for the Korean market


U.S. FDA issues Emergency Use Authorisation for Merck’s molnupiravir
News | December 24, 2021

U.S. FDA issues Emergency Use Authorisation for Merck’s molnupiravir

The authorization provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally